Latest News

Media Release: New report calls for major change to Pharmac’s funding model

October 15, 2024 | Media, News, Press Release, Progressive

Pharmac’s decision-making process for funding drugs in Aotearoa New Zealand is in need of a major overhaul – according to a new independent report. The Milne Report, commissioned by Multiple Sclerosis New Zealand (MSNZ), says its time Pharmac based its […]


Major announcement: Pharmac Initiates Consultation to fund Ocrelizumab for Primary Progressive MS.

June 22, 2023 | Advocacy, Funding, Media, Progressive

Multiple Sclerosis New Zealand (MSNZ) is delighted to share that Pharmac have commenced consultation to fund Ocrelizumab for Primary Progressive MS. Currently, those with PPMS have no access to any disease modifying therapies. Ocrelizumab has been proven in trials to […]


Covid-19 in Ocrelizumab-treated people with Multiple Sclerosis

January 26, 2021 | Covid-19, Life with MS, Research, Treatments

This article, written by the Journal of Multiple Sclerosis and related disorders,  (MSARD) includes data from clinical trials, post marketing safety surveillance and a US electronic medical records database, Optum. The objective was to better understand the SARS-CoV-2 infection in […]